Publications
164
Citations
8,133
Est. group size
—
Recurring co-author estimate
Active years
45
Publishing since 1982
Robert M. Pascuzzi studies neuromuscular disorders, with a strong focus on myasthenia gravis and related conditions such as Lambert-Eaton myasthenic syndrome and amyotrophic lateral sclerosis (ALS). Much of the recent work involves clinical trials testing new treatments (for example, the antibody-based drug rozanolixizumab and immunoglobulin therapy) as well as genetic and molecular studies of these diseases. The research is largely applied, aiming to improve diagnosis and treatment for patients with autoimmune and degenerative nerve-muscle conditions.
Publication activity has been variable across the decade but has increased notably in recent years (2024-2025), averaging about 4.4 papers per year over the last five years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026
Typically publishes in teams of ~13 · 14% small-team papers (≤3 authors) · across 18 venues
- Response to Rozanolixizumab Across Treatment Cycles in Patients With Generalized Myasthenia Gravis: A Post Hoc Analysis of Final Pooled Phase Three Data (P9-9.004)
Neurology · 2026
- Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series
The Lancet · 2025
- Whole-genome bisulfite sequencing of cell-free DNA unveils age-dependent and ALS-associated methylation alterations
Cell & Bioscience · 2025
- Effect of Rozanolixizumab on Ocular Symptoms in Patients with Generalized Myasthenia Gravis: A Post Hoc Item-level Analysis of Myasthenia Gravis-specific Outcomes in MycarinG (P1-11.006)
Neurology · 2025
- Improvement in Patient‐Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PRO
European Journal of Neurology · 2025
- Correlation Between MG Symptoms PRO and Existing MG-Specific Outcome Scores in the Phase 3 MycarinG Study: Post Hoc Analysis (P1-11.026)
Neurology · 2025
- 3595 Effect of rozanolixizumab on ocular symptoms in generalised myasthenia gravis: <i>post hoc</i> item-level analysis of myasthenia gravis-specific outcomes in MycarinG
2025
- Measuring the effect of rozanolixizumab using the Myasthenia Gravis Impairment Index: analyses from the randomized phase 3 MycarinG study
Journal of Neurology · 2025
- Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double‐blind, placebo‐controlled trial
Muscle & Nerve · 2024
- Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study
Therapeutic Advances in Neurological Disorders · 2024
- Drivers of New Rozanolixizumab Treatment Cycles in Patients with Generalized Myasthenia Gravis in the Phase 3 MycarinG and Open-label Extension Studies (P10-11.003)
Neurology · 2024
- Response to Rozanolixizumab Across Treatment Cycles in Patients with Generalized Myasthenia Gravis: A Post-hoc Analysis (P10-11.005)
Neurology · 2024
- 2999 Response to rozanolixizumab across treatment cycles in patients with generalised myasthenia gravis: a<i>post hoc</i>analysis
2024
- 01O Response to rozanolixizumab across treatment cycles in patients with generalised myasthenia gravis: a post hoc analysis
Neuromuscular Disorders · 2024
- 21088. RESPUESTA A ROZANOLIXIZUMAB A TRAVÉS DE CICLOS DE TRATAMIENTO EN PACIENTES CON MIASTENIA GRAVIS GENERALIZADA: UN ANÁLISIS POST HOC
Neurology Perspectives · 2024
- Neurology×16
- Muscle & Nerve×4
- IUScholarWorks (Indiana University)×2
- New England Journal of Medicine×1
- The Lancet Neurology×1
- Miriam Freimer
Medicine · The Ohio State University
- Song Ouyang
Medicine · The Ohio State University
- Cynthia Bodkin
Medicine · Indiana University
- Kenneth A. Kesler
Medicine · Indiana University
- Patrick J. Loehrer
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Sep 1, 2026.
Claim or correct this profile